secwatch / observer
8-K filed April 6, 2022, 7:59 PM ET ticker BPTH CIK 0001133818
leadership confidence high sentiment neutral materiality 0.35

Bio-Path appoints Aline Sherwood to board, regains Nasdaq compliance

BIO-PATH HOLDINGS, INC.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Martina Molsbergen

Director
BPTH · BIO-PATH HOLDINGS, INC.
Effective
2022-02-14
Successor
Aline Sherwood
Filed
April 6, 2022, 7:59 PM ET
On February 14, 2022, Martina Molsbergen resigned from her position as a member of the Board of Directors (the “Board”) of Bio-Path Holdings, Inc. (the “Company”) and all committees of the Board on which she served.
Appointed

Aline Sherwood

Director
BPTH · BIO-PATH HOLDINGS, INC.
Effective
2022-03-31
Filed
April 6, 2022, 7:59 PM ET
On March 31, 2022, the Board appointed Aline Sherwood to the Board to fill the vacancy resulting from the resignation of Ms. Molsbergen.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Martina Molsbergen resigned as Director at BIO-PATH HOLDINGS, INC..

Action
resigned
Role
Director
Exact text from the filing
On February 14, 2022, Martina Molsbergen resigned from her position as a member of the Board of Directors (the “Board”) of Bio-Path Holdings, Inc. (the “Company”) and all committees of the Board on which she served.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Aline Sherwood was appointed as Director at BIO-PATH HOLDINGS, INC..

Action
appointed
Role
Director
Exact text from the filing
On March 31, 2022, the Board appointed Aline Sherwood to the Board to fill the vacancy resulting from the resignation of Ms. Molsbergen.
View on SEC.gov

BIO-PATH HOLDINGS, INC. filing history →

Source: SEC EDGAR
accession 0001558370-22-005126
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.